The Pharma Data

MAY 26, 2023

More ways, to save more lives, for less money: World Health Assembly adopts more Best Buys to tackle noncommunicable diseases The World Health Organization has expanded the list of ‘NCD best buys’. The report is part of the NCDs Global Action Plan 2023-2030 and is an update from 2017 and is core to the Implementation Roadmap on NCDs.

Disease 52

Disease Government Treatment Production 52

The Pharma Data

NOVEMBER 15, 2020

Diadem’s Minimally Invasive Blood-Based AlzoSure® Prognostic Test for Early Alzheimer’s Disease Selected for Potential to Help Transform Management of this Devastating Global Disorder. “Alzheimer’s disease and other dementias afflict more than 50 million people worldwide. . MILAN , Nov.

Disease 40

Disease Treatment Production Clinical Trials 40

Drug Target Review

SEPTEMBER 22, 2023

The substantial value of organoids is becoming increasingly recognised by supportive government initiatives developing novel drugs, with a growth rate of 22 percent between 2023 and 2030 and a market size predicted to reach over US $6.5 billion by 2030. CRISPR engineering in organoids for gene repair and disease modelling.

Clinical Research 116

Clinical Research Research Drug Development Molecular Biology 116

The Pharma Data

APRIL 12, 2022

WHO welcomes the establishment of a new Heads of State and Government Group to accelerate progress towards the SDG target for noncommunicable diseases ? a one-third reduction in “premature” deaths from diseases like diabetes, cancer, heart and lung disease and the promotion of mental health and well-being.

International 52

International Disease Government Treatment 52

The Pharma Data

OCTOBER 9, 2021

Food and Drug Administration (FDA) for the treatment of people living with Alzheimer’s fever ( Notice). This Refinement Therapeutic Designation reinforces our confidence in gantenerumab, which would be the first subcutaneous specific for the treatment of Alzheimer’s trouble with the prospect for at- home administration.”

Disease 52

Disease FDA Therapies Trials 52

The Pharma Data

OCTOBER 14, 2021

Food and Drug Administration (FDA) for the treatment of people living with Alzheimer’s disease (AD). “This Breakthrough Therapy Designation reinforces our confidence in gantenerumab, which would be the first subcutaneous medicine for the treatment of Alzheimer’s disease with the potential for at-home administration.

Therapies 52

Therapies Disease FDA Trials 52

Drug Target Review

DECEMBER 4, 2023

What’s more, investment in this sector is predicted to rise by 70 percent by 2030. Tailoring medical care to a patient’s unique genetic makeup, alongside the close analysis of disease progression, leads to more effective treatments, reduced side effects and faster diagnoses.

Treatment 105

Treatment Science DNA Doctors 105

The Pharma Data

MARCH 2, 2021

Boehringer Ingelheim and Gubra today announced a new research and licensing agreement focused on the identification and validation of targets and innovative peptide compounds for the treatment of obesity. Senior Vice President and Global Head of Cardiometabolic Diseases Research, Boehringer Ingelheim. population will have obesity.

Treatment 52

Treatment Bioinformatics Clinical Development Therapies 52

The Pharma Data

JUNE 28, 2021

Food and Drug Administration (FDA) granted Breakthrough Therapy designation for donanemab, Eli Lilly and Company’s (NYSE: LLY) investigational antibody therapy for Alzheimer’s disease (AD). Dementia due to Alzheimer’s disease is the most common form of dementia, accounting for 60 to 80 percent of all cases 1.

Therapies 40

Therapies Disease Treatment FDA Approval 40

The Pharma Data

NOVEMBER 2, 2020

million people were treated for lymphatic filariasis (LF) in 38 countries that implemented mass drug administration (MDA) of populations at risk of the disease, as recommended by the World Health Organization (WHO). billion cumulative treatments to more than 923 million people since 2000. Setting sights on 2030. In 2019, 538.1

Packaging 52

Packaging Disease Treatment Drugs 52

The Pharma Data

JANUARY 26, 2021

27, 2021 /PRNewswire/ — BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the European Patent Office (EPO) has issued a decision to grant European patent EP 2 448 968 B1 for novel antibodies that could be developed into a treatment for Alzheimer’s disease. STOCKHOLM , Jan.

Disease 40

Disease Pharmaceutical Companies Treatment Licensing 40

The Pharma Data

MARCH 11, 2021

Access to broader reliable diagnostic solutions helps healthcare communities working to expedite and increase disease elimination programs. Roche’s Global Access Program provides innovative diagnostic solutions improving disease and patient ma. Without accurate diagnosis, appropriate disease management may be delayed.

Disease 52

Disease Treatment Laboratories Virus 52

The Pharma Data

APRIL 7, 2021

Thirty of Sanofi’s medicines will be provided across a wide range of therapeutic areas, including cardiovascular disease, diabetes, tuberculosis, malaria and cancer. Leveraging R&D efforts to address crucial treatment gaps. Leveraging R&D efforts to address crucial treatment gaps.

Vaccine 52

Vaccine Packaging Disease Treatment 52

DrugBank

NOVEMBER 4, 2024

trillion loss in GDP by 2030 shows the urgency of this crisis.  This decline in R&D is attributed to scientific challenges associated with identifying new antibiotic targets and the relatively low return on investment compared to other therapeutic areas like oncology or rare diseases.  million deaths associated with it.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceuticals Government DNA 98

The Pharma Data

FEBRUARY 21, 2022

Such success stories are encouraging and help us to eliminate more diseases in our Region.”. The disease. Trachoma is a devastating eye disease caused by infection with the bacterium Chlamydia trachomatis. To eliminate trachoma, WHO recommends the SAFE strategy 2 to achieve elimination of trachoma as a public health problem.

Disease 52

Disease Treatment International Drugs 52

The Pharma Data

MARCH 9, 2021

New data from 10 studies will be presented by Eli Lilly and Company (NYSE: LLY) at the upcoming virtual International Conference on Alzheimer’s & Parkinson Diseases 2021 (AD/PD 2021), March 9-14, 2021. vice president of Alzheimer’s disease development unit, Eli Lilly and Company.

Disease 40

Disease International Research Therapies 40

The Pharma Data

APRIL 24, 2021

The COVID-19 pandemic highlights the importance of robust health systems to respond to disease outbreaks and to control other deadly diseases such as malaria. Over the past 20 years, together with our partners, we have delivered nearly 1 billion treatments, including over 430 million pediatric treatments to malaria-endemic countries.

Clinical Trials 52

Clinical Trials Treatment Trials Disease 52

The Pharma Data

NOVEMBER 1, 2020

MS is an autoimmune, inflammatory disease of the central nervous system. billion by 2030 2. BTK inhibitors have the potential to transform the treatment paradigm of autoimmune diseases including MS. The trial is expected to enroll 160 patients. billion in 2018, and it is expected to be up to US$48.9

Clinical Trials 40

Clinical Trials Trials FDA Treatment 40

New Drug Approvals

JANUARY 31, 2024

In addition to hyperlipidemia and type 2 diabetes, a marked increase in the prevalence of non-alcoholic fatty liver disease (NAFLD) has occurred. The present invention addresses these needs for new treatment methods, compounds, and pharmaceutical compositions. Current drugs that treat hyperlipidemia (e.g., Skjaeret, et al.

Treatment 52

Treatment Disease Pharmaceuticals Drugs 52

The Pharma Data

MARCH 13, 2021

Further, prespecified exploratory analyses showed donanemab slowed the accumulation of tau across key brain regions in patients affected by Alzheimer’s disease. “This is the first late-stage study in Alzheimer’s disease to meet its primary endpoint at the primary analysis.

Disease 40

Disease Trials Treatment Medical Schools 40

Vial

APRIL 18, 2024

Yet, hereditary and age-related retinal diseases present challenges, often leading to progressive vision loss and potential blindness. Market research indicates significant growth in the ophthalmic clinical trials market, driven by increased disease prevalence, demand for ocular treatments, and rising research funding.

Clinical Trials 52

Clinical Trials Trials Treatment Clinical Research 52

The Pharma Data

SEPTEMBER 28, 2020

Cardiovascular disease (CVD) is a general term for conditions affecting the heart or blood vessels. CVD has many causes: from smoking, diabetes, high blood pressure and obesity, to air pollution, genetic risk factors and less common conditions such as Chagas disease. Developing next-generation therapies.

Disease 52

Disease Therapies Treatment Clinical Research 52

The Pharma Data

NOVEMBER 29, 2020

The World Health Organization (WHO) is calling on countries and global health partners to step up the fight against malaria, a preventable and treatable disease that continues to claim hundreds of thousands of lives each year. The disease claimed some 409 000 lives in 2019 compared to 411 000 in 2018. WHO response.

Disease 52

Disease International Treatment Drugs 52

NIH Director's Blog: Drug Development

MAY 15, 2018

Credit: National Institute of Allergy and Infectious Diseases, NIH As a volunteer physician in a small hospital in Nigeria 30 years ago, I was bitten by lots of mosquitoes and soon came down with headache, chills, fever, and muscle aches. In fact, the treatment that cured me would be of little use today. World Health Organization.

Drug Development 52

Drug Development Drugs Disease Treatment 52

The Pharma Data

MARCH 24, 2021

Successfully identifying these people, especially those living with multidrug-resistant TB (MDR-TB), remains one of the most significant obstacles in achieving the United Nations (UN) Sustainable Development Goal of ending TB by 2030. Vice Chairman of the Executive Committee and Chief Scientific Officer of Johnson & Johnson.

Treatment 52

Treatment Disease Government International 52

The Pharma Data

NOVEMBER 16, 2020

WHO‘s Global Strategy to Accelerate the Elimination of Cervical Cancer, launched today, outlines three key steps: vaccination, screening and treatment. Successful implementation of all three could reduce more than 40% of new cases of the disease and 5 million related deaths by 2050. Cervical cancer is a preventable disease.

Vaccine 40

Vaccine Treatment Disease Engineering 40

The Pharma Data

JULY 29, 2021

P-tau217 in blood showed promise as additional biomarker of efficacy- Donanemab treatment led to 24% lowering of P-tau217 from baseline. Donanemab is also being studied in the ongoing Phase 3 TRAILBLAZER-ALZ 2 study in early, symptomatic Alzheimer’s disease patients. vice president of pain and neurodegeneration, Lilly.

Disease 52

Disease Treatment Pharmacokinetics Trials 52

Drug Target Review

OCTOBER 1, 2024

The possibility of using new technologies to build new, more effective and less toxic therapies has opened new horizons for the treatment of cancer. Moreover, increasing treatment complexity will require more sophisticated scientific exchange. Oncology has come a long way in recent years.

Doctors 97

Doctors Therapies Science Pharma Companies 97

The Pharma Data

FEBRUARY 21, 2022

In the area of cardiovascular disease, Bayer is delivering on its late-stage pipeline including recent launches of Kerendia™ (finerenone) and Verquvo™ (vericiguat). “We Our scientific leadership in the area of cardiovascular diseases advances our mission to provide better treatment options for patients in need.”.

Clinical Trials 52

Clinical Trials Small Molecule Clinical Development Disease 52

The Pharma Data

JULY 15, 2021

Trial will include participants at risk for cognitive and functional decline related to Alzheimer’s disease. TRAILBLAZER-ALZ 3 will evaluate whether treatment with donanemab can slow the clinical progression of Alzheimer’s disease in trial participants. vice president of pain and neurodegeneration, Lilly.

Trials 52

Trials Therapies Clinical Trials Disease 52

The Pharma Data

JULY 11, 2021

Tuberculosis is a disease of poverty, and economic distress with 1.4 Tuberculosis is a disease of poverty, and economic distress with 1.4 High-volume, multi-disease testing systems and innovative diagnostic tests can accelerate eradication efforts and further improve health outcomes for people living with TB.

Disease 52

Disease Laboratories Treatment Government 52

DrugBank

FEBRUARY 19, 2025

billion by 2030, the sector is witnessing a shift in how drugs are conceived, developed, and tested.  Historically, the target identification process has been fraught with challenges due to the sheer complexity of diseases and the large volume of data that needs to be analyzed. billion in 2023 to $7.9

Clinical Trials 52

Clinical Trials Drugs Trials Treatment 52

The Pharma Data

FEBRUARY 24, 2022

– Heart failure represents a significant, growing disease burden in the U.S., with more than 8 million cases expected by 2030. with preserved ejection fraction, a form of heart failure that has very limited treatment options.” ” Affecting more than 6 million people in the U.S.,

FDA Approval 52

FDA Approval FDA Hospitals Trials 52

Olympian Clinical Research

JULY 12, 2022

There are several types of depression, each with its own set of symptoms and recommended treatment methods. According to the World Health Organization, major depressive disorder is projected to rank first as the top burden of disease worldwide by 2030. As a result, many people do not seek treatment. Hypochondria.

Clinical Research 94

Clinical Research Doctors Treatment Research 94

The Pharma Data

FEBRUARY 22, 2022

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “ We are making great progress on our ambition to be zero carbon across our global operations by the end of 2025 and carbon negative across our entire value chain by 2030. AstraZeneca is an established leader in respiratory care with a 50-year heritage.

Science 52

Science Disease Pharmaceuticals Pharmaceutical Companies 52

The Pharma Data

MAY 17, 2023

“Following Benin’s and Mali’s success, trachoma remains endemic in 23 countries in WHO’s African Region, bringing us a step closer towards the elimination target for trachoma set in the road map for neglected tropical diseases 2021–2030.” The disease is caused by infection with the bacterium Chlamydia trachomatis.

Disease 40

Disease International Treatment 40

The Pharma Data

MAY 26, 2023

With our leading portfolio of medicines in lung cancer, our ambition is to have the right AstraZeneca medicine for more than half of all patients with this disease by 2030. These include.

Therapies 40

Therapies Trials Treatment Disease 40